(MISSOULA) A new study looking at a possible new treatment for military-related Post Traumatic Stress Disorder is starting up in Missoula.
Providence St. Patrick Hospital, the University of Montana and Tonix Pharmaceuticals announced the opening of a clinical study site on Monday which could involve as many as 550 Montana veterans.
The drug Tonmya is said to be a breakthrough therapy for PTSD, so much so, that the US Food and Drug Administration is giving the go-ahead to accelerate and develop the studies on this drug. Tonmya is believed to target parts of the brain which are associated with disturbed sleep and nightmares.
Increasing sleep quality for people who suffer from PTSD may ease the body's ability to recover from severe trauma, according to Tonix Pharmaceuticals.
Eligible veterans are those who have experienced one or more traumatic events during military service since 2001 and are experiencing ongoing symptoms like flashbacks, irritability, and agitation.
Matt Kuntz with NAMI Montana believes remission of PTSD is something to look forward to and participates are helping more than themselves.
"You’re not just helping yourself, you're helping the guy and the gal behind you that is still struggling,” Kuntz said. “My grandfather had PTSD from WWII and my step-brother had PTSD from Iraq. This is a chance to participate in something that might change the trajectory of how we treat PTSD over the long term.”
To participate in the trial, Montana veterans can visit TheHonorStudy.com to see if they qualify and to enroll. If veterans qualify and choose to participate, they will receive study-related care at no cost.
Veterans also will receive compensation for time and travel to attend study visits. Health insurance is not required to participate in the study, and a Certificate of Confidentiality is provided to participants to protect their privacy.